Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 182,000 shares, an increase of 70.4% from the May 15th total of 106,800 shares. Based on an average daily trading volume, of 4,260,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 24.3% of the company’s stock are sold short.

Windtree Therapeutics Stock Performance

Shares of Windtree Therapeutics stock opened at $0.59 on Monday. Windtree Therapeutics has a one year low of $0.52 and a one year high of $737.44. The company has a market cap of $2.17 million, a PE ratio of -0.04 and a beta of 0.77. The business has a 50-day simple moving average of $0.94 and a 200-day simple moving average of $6.32.

Windtree Therapeutics (NASDAQ:WINT) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($4.63) EPS for the quarter, topping analysts’ consensus estimates of ($39.00) by $34.37. On average, sell-side analysts predict that Windtree Therapeutics will post -5.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC purchased a new stake in Windtree Therapeutics, Inc. (NASDAQ:WINT) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics as of its most recent SEC filing. 29.33% of the stock is owned by institutional investors and hedge funds.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.